OncologyConsults.com - Immunotherapy for the Treatment of Non-Small Cell Lung Cancer is organized by Johns Hopkins Medicine (JHM).
Release date: May 3, 2018
Expiration date: May 3, 2020
This activity is intended for oncology healthcare providers (physicians, advanced practice nurses, and registered nurses) who care for patients with NSCLC. No prerequisites required.
Credit Designation Statements:
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until May 2, 2020.
Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). Of those with NSCLC, approximately 40% present with advanced unresectable disease. For decades, chemotherapy has been the standard of care for patients without mutations who are sensitive to targeted therapy. However, chemotherapy only provides limited therapy with a limited safety profile. Immunotherapy is a new approach to treating patients with NSCLC. Immune checkpoint blockade increases antitumor immunity by blocking down-regulators of immunity, such as programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1). Several clinical trials have consistently demonstrated superior efficacy of several immune checkpoint-directed antibodies (ie, nivolumab, pembrolizumab, and atezolizumab) in treating patients with advanced NSCLC. This case activity will provide clinicians who treat and manage patients with advanced stage NSCLC with the most up-to-date information on the most effective treatment options, specifically with immunotherapies.
The goal of this activity is to provide the most up-to-date information about the role of immune checkpoint inhibitors PD-1 and PD-L1 inhibitors in the treatment of patients with NSCLC.
After participating in this activity, the participant will demonstrate the ability to:
• Outline essential concepts of adaptive immune responses with regards to NSCLC immunotherapy.
• Identifythe efficacy and safety of novel and investigational NSCLC immunotherapies.
• Incorporate novel NSCLC immunotherapies into treatment plans based on treatment algorithms and recommendations.
Additional details will be posted as soon as they are available.